The company’s consolidated net profit during the quarter under review increased by 5.9% at Rs 353 million against Rs 333 million in the corresponding quarter of previous fiscal. Gross revenue grew 19% to Rs 1,463 million over the previous year quarter.
Caplin Point Laboratories' net profit growth was lowest since September 2013 quarter, while revenue growth was lowest since March 2013.
At 11:52 am; the stock was trading 9% lower at Rs 542 on the BSE as compared to 0.10% rise in the S&P BSE Sensex. It was quoting close to its 52-week low of Rs 525 touched on June 2, 2017 on the BSE in intra-day trade. The trading volumes on the counter jumped multiple-fold with a combined 137,853 shares changed hands on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)